The adenovirus type 5 E1A is associated with multiple anti-tumor activities including the downregulation of the overexpressed HER-2, the repression of metastasis-promoting activities, the enhancement of sensitivity of cancer cells to genotoxic agents (apoptosis inducers), and etc. Our previous studies using E1A gene coupled with cationic liposome had shown that it was an effective gene therapy approach to treat cancer in orthotopic animal models. Based on thrse achievements, multiple clinical trials using E1A/liposome were approved to target solid tumors of the breast, ovary, and head and neck via intrathoracic, intraperitoneal, and intratumor injections, respectively. We were able to show in the Phase I trial that these E1A/liposome treatments, when treated locally and at safe dosage, could result in downregulation of HER-2 and sensitization to apoptosis in tumor cells of the treated patients. Although the phase I trial data is encouraging and has proved the concept that E1A gene therapy is able to sensitize tumor cell death in humans, the E1A/liposome complex was administrated locally to the thoracic cavity via catheters in breast cancer patients. However, metastatic breast cancer is a systemic disease, and systemic delivery of a therapeutic agent is required to achieve effective therapy. Therefore, it is critical to develop systemic delivery systems of E1A gene therapy for metastatic breast cancer patients. We have recently used a newly developed non-viral systemic delivery system, LPD, and demonstrated suppressed tumor growth in an orthotopic breast cancer animal model through a systemic delivery of E1A gene by intravenously injection. In this proposal, we will continue our investigation on the therapeutic effects of the E1A/LPD gene therapy in the breast animal model through systemic delivery. We also propose a clinical trial using this system to test the therapeutic efficacy in breast cancer patients. In addition, we will continue our study to further elucidate the molecular mechanisms underlying the E1A-mediated sensitization to Taxol- and TNF-alpha-induced apoptosis in breast cancer cells and that will provide a scientific basis for us to develop combined therapy using E1A gene and Taxol (or TNF-alpha). The long-term goal of this proposal is to translate our previous laboratory discovery of E1A gene as a tumor suppressor gene into an effective therapeutic agent for breast cancer patients in clinic.
The Specific Aims of this proposal are: 1. To investigate the E1A-mediated sensitization to Taxol-induced apoptosis in breast cancer cells. 2. To investigate the E1A-mediated sensitization to TNF-alpha-induced apoptosis in breast cancer cells. 3. To develop a tumor specific promoter using hTERT promoter-driven E1A for breast cancer gene therapy. 4. To develop E1A clinical trials for metastatic cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA058880-07
Application #
6266232
Study Section
Special Emphasis Panel (ZRG1-MEP (01))
Program Officer
Wolpert, Mary K
Project Start
1993-02-02
Project End
2005-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
7
Fiscal Year
2001
Total Cost
$224,448
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Lee, Dung-Fang; Kuo, Hsu-Ping; Chen, Chun-Te et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130:440-55
Yang, Jer-Yen; Xia, Weiya; Hu, Mickey C-T (2006) Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29:643-8
Kumar, Rakesh; Hung, Mien-Chie (2005) Signaling intricacies take center stage in cancer cells. Cancer Res 65:2511-5
Hu, Mickey C-T; Hung, M C (2005) Role of IkappaB kinase in tumorigenesis. Future Oncol 1:67-78
Li, Yan M; Zhou, Binhua P; Deng, Jiong et al. (2005) A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 65:3257-63
Ding, Qingqing; Xia, Weiya; Liu, Jaw-Ching et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19:159-70
Shao, Ruping; Lee, Dung-Fang; Wen, Yong et al. (2005) E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res 3:219-26
Xia, Weiya; Chen, Jin-Shing; Zhou, Xian et al. (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10:3815-24
Royce, Melanie E; Xia, Weiya; Sahin, Aysegul A et al. (2004) STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 100:12-9
Liao, Yong; Hung, Mien-Chie (2004) A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res 64:5938-42

Showing the most recent 10 out of 89 publications